ArticleACS omega2026
μPADs for a Safer Night's Sleep: An Alternative for Quality Control of Melatonin Pharmaceutical Formulations.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin, known as the "sleep hormone," has its primary function in regulating the circadian cycle, a 24 h sleep-wake pattern that leads to significant physical, mental, and behavioral changes. The use of melatonin in pharmaceutical formulations gained popularity as a tool to combat sleep disorders such as insomnia and has been increasing in the last few decades. Melatonin-based pharmaceutical formulations are classified as dietary supplements, which leads to a different perspective on the necessity of strict quality control for these products. There are already extensive descriptions in the literature of the serious side effects associated with the administration of those formulations, including, for example, higher dosages than indicated on the label or contamination by other hormones. Still, there is a gap in devices that could make an easy and low-cost determination of melatonin. This work presents a paper-based sensor for the quality control of melatonin in pharmaceutical formulations, utilizing the modified Van Urk reaction. This reaction causes a color change from white to blue on the paper surface, correlating with the melatonin concentration. The constructed sensor performed well in quantifying melatonin in solid (0.22 mg/tablet) and liquid (0.20 mg/drop) pharmaceutical formulations, considering the maximum standard deviation when compared with results obtained by a gold-standard technique (liquid chromatography). The developed method demonstrated good linearity (R
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.